ArticleClinical and molecular hepatology2025

Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".

Hiroaki Kanzaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.